Does lactate clearance prognosticates outcomes in ECMO therapy: a retrospective observational study

BMC Anesthesiology

Table 3 Lactate levels, lactate clearance-1 at specific time points and lactate clearance-2 were compared

	All (n = 48)	Survivors (n = 14)	Non-survivors (n = 34)	p-value^*
LL pre-ECMO (mmol/l)	10.9 ± 5.4	7.6 ± 2.7	12.3 ± 5.7	0.008
LL post-ECMO (mmol/l)	10.0 ± 5.4	6.4 ± 2.6	11.5 ± 5.6	0.003
LL postECMO- LL preECMO (mmol/l)	−0.9 ± 0.8	−1.2 ± 0.6	−0.9 ± 0.8	0.002
LC-1 6 h (mmol/l)	−1.8 ± 4.4	−3.2 ± 1.1	− 1.8 ± 4.4	0.017
LC-1 24 h (mmol/l)	−3.6 ± 5.6	−4.6 ± 2.2	− 3.6 ± 5.6	0.634
LC-1 48 h (mmol/l)	−2.9 ± 6.2	−5.5 ± 2.6	−2.9 ± 6.2	0.023
LC-2 (hours)	7.0 ± 6.1	1.3 ± 1.3	9.4 ± 5.8	< 0.001

Subgroups (The survivors versus Non-the survivors) refer to 30-day mortality. p-values calculated for comparison of the survivors versus non-the survivors by statistical analysis
Data are mean ± SD or n (%)
^*Determined by Mann-Whitney U test or Spearman’s rho test
Abbreviations: ECMO extracorporeal membrane oxygenation, LL lactate level at specific time, LC-1 lactate clearance at specific time, LC-2 the duration between ECMO implantation time and time point that Lactate cleared more than 10% of the initial level

ISSN: 1471-2253